Alsaud Arwa, Mohamed Shehab, Yassin Mohamed A, Ashour Amr, Obeidat Khaldun, Azrieh Bahjat
Hamad Medical Corporation, Doha, Qatar.
Case Rep Oncol. 2020 Mar 5;13(1):207-211. doi: 10.1159/000505686. eCollection 2020 Jan-Apr.
Papillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivors including acute myeloid leukemia (AML) as an infrequent cancer related to RAI therapy; it has a higher relative risk ratio in patients on higher doses of radiation exposure. We would like to report a 30-year-old lady who was diagnosed with papillary thyroid carcinoma. She underwent total thyroidectomy and received a low-dose RAI I therapy at a dose of 150 mCi, after which she developed therapy-related AML. Here we would like to highlight the association of AML with low-dose RAI as an infrequent cause of a second primary tumor compared to high doses.
乳头状甲状腺癌是最常见的原发性甲状腺癌。其治疗大多采用手术切除，部分病例需要放射性碘（RAI）治疗。研究表明，在接受RAI治疗的甲状腺癌幸存者中，第二原发性恶性肿瘤的发生率有所增加，其中急性髓系白血病（AML）是一种与RAI治疗相关的罕见癌症；在接受高剂量辐射的患者中，其相对风险比更高。我们报告一名30岁女性，她被诊断为乳头状甲状腺癌。她接受了全甲状腺切除术，并接受了剂量为150毫居里的低剂量RAI I治疗，之后她患上了与治疗相关的AML。在此，我们想强调与高剂量相比，低剂量RAI作为第二原发性肿瘤罕见病因与AML的关联。
